Home Featured Page 128

Featured

Latest

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Numinus to Participate in a Water Tower Research Fireside Chat on...

Reunion Neuroscience Inc. Announces Executive Changes

PT362 – Cory Firth – Psychedelic Storytelling: Transforming Out Loud

Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health

Silo Pharma to Present at the Dawson James Small Cap Growth...

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October...

MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference

Numinus Develops Mushroom Tea for Use in Psychedelic Research

Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its...

PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s...

1...127128129...292 Page 128 of 292

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Numinus to Participate in a Water Tower Research Fireside Chat on...

Reunion Neuroscience Inc. Announces Executive Changes

PT362 – Cory Firth – Psychedelic Storytelling: Transforming Out Loud

Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health

Silo Pharma to Present at the Dawson James Small Cap Growth...

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October...

MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference

Numinus Develops Mushroom Tea for Use in Psychedelic Research

Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its...

PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s...

EDITOR PICKS

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY